GlycoMimetics Inc (GLYC NASDAQ) stock market data APIs
$0.2486
0(0%)
as of May 16, 2025
Try our APIs with
free plan!
GlycoMimetics Inc Financial Data Overview
GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.
Prev. Close
0.2486
Open
0.2522
High
0.2664
Low
0.2486
52 wk Range
0.1406-0.63
Market Cap
15 935 K
Shares Outstanding
64 514 K
Revenue
10 000
EPS
-0.04
Beta
1.699
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GlycoMimetics Inc data using free add-ons & libraries
Get GlycoMimetics Inc Fundamental Data
GlycoMimetics Inc Fundamental data includes:
- Net Revenue: 10 000
- EBITDA: -23 763 576
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GlycoMimetics Inc News
New
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRA, FARO, AVDX, GLYC on Behalf of Shareholders
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or brea...
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC, BRZH, PRA, FVNNU
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the...
Crescent Biopharma Appoints David Lubner to Board of Directors
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnol...
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick Scalzo, MBA, as Chief Financial Offic...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
